Company Overview and News

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - 10 LN66 [BARC-AMERICAS.FID1003735] (Prospectus)

58m sec.gov
Pricing Supplement dated October 16, 2018 (To the Prospectus dated March 30, 2018, the Prospectus Supplement dated July
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - 10 LN76 [BARC-AMERICAS.FID1004657] (Prospectus)

58m sec.gov
Pricing Supplement dated October 17, 2018 (To the Prospectus dated March 30, 2018, the Prospectus Supplement
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - 10 LN82 [BARC-AMERICAS.FID1005133] (Prospectus)

59m sec.gov
Pricing Supplement dated October 16, 2018 (To the Prospectus dated March 30, 2018, the Prospectus Supplement dated July 1
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 FORM 424B2 (Prospectus)

1h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus and prospectus supplement do not constitute an offer to sell the securities and we are not soliciting an offer to buy the securities in any state where th
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - JEFFERIES [BARC-AMERICAS.FID1005732] (Prospectus)

1h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus and prospectus supplement do not constitute an offer to sell these securities,
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 FORM 424B2 (Prospectus)

9h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus, prospectus supplement and index supplement do not constitute an offer to sell the Notes and we are not soliciting an offer to buy the Notes in any state where the
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 FORM 424B2 (Prospectus)

9h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus, prospectus supplement and index supplement do not constitute an offer to sell the PLUS and we are not soliciting an offe
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 FORM 424B2 (Prospectus)

9h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus, prospectus supplement and index supplement do not constitute an offer to sell the Notes and we are not soliciting an offer to buy the Notes in any state where the
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 10 LN84 [BARC-AMERICAS.FID1005351] (Prospectus)

9h sec.gov
The information in this pricing supplement is not complete and may be changed. This pricing supplement and the accompanying prospectus, prospectus supplement and index supplement do not constitute an offer to sell these Notes,
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 10 LN86 [BARC-AMERICAS.FID1005434] (Prospectus)

9h sec.gov
The information in this pricing supplement is not complete and may be changed. This pricing supplement and the accompanying prospectus, prospectus supplement, and index supplement do not constitute an offer to sell these Notes,
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - 10 LN85 [BARC-AMERICAS.FID1005437] (Prospectus)

9h sec.gov
The information in this pricing supplement is not complete and may be changed. This pricing supplement and the accompanying prospectus, prospectus supplement and index supplement do not constitute an offer to sell these Notes,
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - 10 LN81 [BARC-AMERICAS.FID1005107] (Prospectus)

2018-10-17 sec.gov
The information in this pricing supplement is not complete and may be changed. This pricing supplement and the accompanying prospectus, prospectus supplement and index supplement do not constitute an offer to sell these Notes,
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - 10 LN77 [BARC-AMERICAS.FID1004750] (Prospectus)

2018-10-17 sec.gov
Pricing Supplement dated October 15, 2018 (To the Prospectus dated March 30, 2018, the Prospectus Supplement dated Jul
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 424B2 - RATES 2YNC6M [BARC-AMERICAS.FID1001761] (Prospectus)

2018-10-17 sec.gov
Pricing Supplement dated October 15, 2018 (To Prospectus dated March 30, 2018 and the Prospectus Supplement dated July 18, 2016)
OIL

 
OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 FORM 424B2 (Prospectus)

2018-10-17 sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying prospectus, prospectus supplement and index supplement do not constitute an offer to sell the Notes and we are not soliciting an offer to buy the Notes in any state where the
OIL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to OIL / Barclays iPath S&P GSCI Crude Oil Total Return Index ETN due on 8/14/2036 on message board site Silicon Investor.

CBD oil CBD oil CBD oil Plastics to Oil - Pyrolysis and Secret Catalysts and Alterna Plastics to Oil - Pyrolysis and Secret Catalysts and Alterna Plastics to Oil - Pyrolysis and Secret Catalysts and Alterna
Canadian Oil u0026 Gas Companies Canadian Oil u0026 Gas Companies Canadian Oil u0026 Gas Companies Peak Oil reality or Myth, of an out of Control System Peak Oil reality or Myth, of an out of Control System Peak Oil reality or Myth, of an out of Control System
Shipping - Oil u0026 Gas Tankers, Dry cargo, LNG Shipping - Oil u0026 Gas Tankers, Dry cargo, LNG Shipping - Oil u0026 Gas Tankers, Dry cargo, LNG Schlumberger - The biggest/baddest oil service company Schlumberger - The biggest/baddest oil service company Schlumberger - The biggest/baddest oil service company
JBII - The Secret Catalyst Turns Plastics into Oil JBII - The Secret Catalyst Turns Plastics into Oil JBII - The Secret Catalyst Turns Plastics into Oil Plastic2Oil, Inc. Plastic2Oil, Inc. Plastic2Oil, Inc.
Shale Natural Gas, Oil and NGLs and ESA Shale Natural Gas, Oil and NGLs and ESA Shale Natural Gas, Oil and NGLs and ESA impose an oil import tax/ tariff on all brent oil imported t impose an oil import tax/ tariff on all brent oil imported t impose an oil import tax/ tariff on all brent oil imported t
CUSIP: 06738C786